Skip to main content

Proto Labs Inc

For the period ended Jun 30, 2026. Filed Jul 31, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 31, 2026

PRLB$69.09+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Financial Statements

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

June 30,2026December 31,2025
(Unaudited)
Assets
Current assets
Cash and cash equivalents$127,918$110,826
Short-term marketable securities14,85817,297
Accounts receivable, net of allowance for credit losses of $3,022 and $2,668 as of June 30, 2026, and December 31, 2025, respectively95,07478,962
Inventory15,41314,401
Prepaid expenses and other current assets11,5909,590
Income taxes receivable1,3902,465
Total current assets266,243233,541
Property and equipment, net208,329215,261
Goodwill273,991273,991
Other intangible assets, net16,60618,612
Long-term marketable securities20,12014,308
Operating lease assets1,2632,836
Finance lease assets290424
Other long-term assets4,4564,442
Total assets$791,298$763,415
Liabilities and shareholders' equity
Current liabilities
Accounts payable$21,542$15,104
Accrued compensation18,83023,674
Accrued liabilities and other31,77626,783
Current operating lease liabilities9291,155
Current finance lease liabilities127286
Total current liabilities73,20467,002
Long-term operating lease liabilities1,1851,606
Long-term deferred tax liabilities20,62516,598
Other long-term liabilities4,5514,277
Total liabilities99,56589,483
Shareholders' equity
Preferred stock, $0.001 par value, authorized 10,000,000 shares; issued and outstanding 0 shares as of June 30, 2026, and December 31, 2025, respectively——
Common stock, $0.001 par value, authorized 150,000,000 shares; issued and outstanding 23,921,897 and 23,627,422 shares as of June 30, 2026, and December 31, 2025, respectively2424
Additional paid-in capital460,671454,120
Retained earnings254,326240,764
Accumulated other comprehensive loss(23,288)(20,976)
Total shareholders' equity691,733673,932
Total liabilities and shareholders' equity$791,298$763,415

Consolidated Statements of Comprehensive Income

(In thousands, except share and per share amounts)

(Unaudited)

Three Months EndedJune 30,Six Months EndedJune 30,
2026202520262025
Statements of Operations:
Revenue$149,341$135,063$288,677$261,268
Cost of revenue79,99975,289155,743145,796
Gross profit69,34259,774132,934115,472
Operating expenses
Marketing and sales25,68224,73150,46248,480
Research and development10,79111,17321,33121,782
General and administrative19,65018,75236,66235,600
Restructuring and transformation costs924—2,345—
Costs related to exit and disposal activities937149937110
Total operating expenses57,98454,805111,737105,972
Income from operations11,3584,96921,1979,500
Other income, net1,2451,7052,7233,159
Income before income taxes12,6036,67423,92012,659
Provision for income taxes3,4512,2476,6574,633
Net income$9,152$4,427$17,263$8,026
Net income per share:
Basic$0.38$0.19$0.72$0.33
Diluted$0.37$0.18$0.71$0.33
Shares used to compute net income per share:
Basic23,969,25423,900,39023,902,80224,018,119
Diluted24,415,78824,101,59224,358,56824,291,246
Comprehensive Income (net of tax)
Comprehensive income$9,351$6,755$14,951$11,447

Consolidated Statements of Shareholders' Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-InCapital · RetainedEarnings · Accumulated OtherComprehensiveLoss · Total
Shares · Amount
Balance at December 31, 202523,627,422$24$454,120$240,764$(20,976)$673,932
Common shares issued on exercise of options and other, net of shares withheld for tax obligations165,066—375——375
Stock-based compensation expense——3,219——3,219
Net income———8,111—8,111
Other comprehensive income
Foreign currency translation adjustment————(2,382)(2,382)
Net unrealized loss on investments in securities————(129)(129)
Comprehensive income5,600
Balance at March 31, 202623,792,488$24$457,714$248,875$(23,487)$683,126
Common shares issued on exercise of options and other, net of shares withheld for tax obligations197,962—204——204
Stock-based compensation expense——4,088——4,088
Repurchases of common stock and other(68,553)—(1,335)(3,701)—(5,036)
Net income———9,152—9,152
Other comprehensive income
Foreign currency translation adjustment————289289
Net unrealized loss on investments in securities————(90)(90)
Comprehensive income9,351
Balance at June 30, 202623,921,897$24$460,671$254,326$(23,288)$691,733
Common Stock · AdditionalPaid-InCapital · RetainedEarnings · Accumulated OtherComprehensiveLoss · Total
Shares · Amount
Balance at December 31, 202424,226,088$24$453,705$244,406$(27,984)$670,151
Common shares issued on exercise of options and other, net of shares withheld for tax obligations58,291—(961)——(961)
Stock-based compensation expense——3,992——3,992
Repurchases of common stock(513,739)(1)(9,621)(11,451)—(21,073)
Net income———3,599—3,599
Other comprehensive income
Foreign currency translation adjustment————1,0031,003
Net unrealized gains on investments in securities————9090
Comprehensive income4,692
Balance at March 31, 202523,770,640$23$447,115$236,554$(26,891)$656,801
Common shares issued on exercise of options and other, net of shares withheld for tax obligations179,393—(58)——(58)
Stock-based compensation expense——4,259——4,259
Repurchases of common stock(75,432)—(1,413)(1,637)—(3,050)
Net income———4,427—4,427
Other comprehensive income
Foreign currency translation adjustment————2,3002,300
Net unrealized gains on investments in securities————2828
Comprehensive income6,755
Balance at June 30, 202523,874,601$23$449,903$239,344$(24,563)$664,707

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Six Months EndedJune 30,
20262025
Operating activities
Net income$17,263$8,026
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization16,16117,264
Stock-based compensation expense7,3078,251
Deferred taxes4,054(3,985)
Interest on finance lease obligations511
Loss on impairment of equipment186—
Impairments related to exit and closure of facilities937448
Gain on disposal of property and equipment(120)—
Other(152)(82)
Changes in operating assets and liabilities:
Accounts receivable(16,397)(9,487)
Inventories(1,131)(983)
Prepaid expenses and other(2,078)338
Income taxes1,0501,836
Accounts payable5,888(654)
Accrued liabilities and other57,980
Net cash provided by operating activities32,97828,963
Investing activities
Purchases of property, equipment and other capital assets(9,743)(2,730)
Proceeds from sales of property, equipment and other capital assets1,279—
Purchases of marketable securities(16,007)(11,052)
Proceeds from maturities of marketable securities12,50010,230
Net cash used in investing activities(11,971)(3,552)
Financing activities
Proceeds from issuance of common stock from equity plans7,2652,081
Purchases of shares withheld for tax obligations(5,951)(3,117)
Repurchases of common stock(5,036)(23,980)
Principal repayments of finance lease obligations(160)(153)
Net cash used in financing activities(3,882)(25,169)
Effect of exchange rate changes on cash and cash equivalents(33)1,069
Net increase in cash and cash equivalents17,0921,311
Cash and cash equivalents, beginning of period110,82689,071
Cash and cash equivalents, end of period$127,918$90,382

Notes to Consolidated Financial Statements

Note 1 –Basis of Presentation

The unaudited interim Consolidated Financial Statements of Proto Labs, Inc. (Protolabs, the Company, we, us or our) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying financial statements reflect all adjustments necessary for a fair presentation of the Company’s statements of financial position, results of operations and cash flows for the periods presented. Except as otherwise disclosed herein, these adjustments consist of normal, recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the audited Consolidated Financial Statements and Notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission (SEC) on February 20, 2026.

The accompanying Consolidated Balance Sheet as of December 31, 2025 was derived from the audited Consolidated Financial Statements but does not include all disclosures required by U.S. GAAP for a full set of financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and Notes included in the Company's Annual Report on Form 10-K filed on February 20, 2026 as referenced above.

Note 2 –Recent Accounting Pronouncements

The Company did not recently adopt any accounting pronouncements that had a material impact on the Company's Consolidated Financial Statements.

Apart from the items discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, there are no other new accounting pronouncements that are expected to have a significant impact on the Company’s consolidated financial statements or related disclosures.

Note 3 –Net Income per Common Share

Basic net income per share is computed based on the weighted-average number of common shares outstanding. Diluted net income per share is computed based on the weighted-average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of common stock include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. Performance stock units are excluded from the calculation of dilutive potential common shares until the performance conditions have been satisfied. Anti-dilutive options were excluded from the calculation of diluted weighted average shares outstanding and were 99,200 and 459,386 for the three months ended June 30, 2026 and 2025, respectively, and 93,525 and 446,174 for the six months ended June 30, 2026 and 2025, respectively.

The table below sets forth the computation of basic and diluted net income per share:

Three Months EndedJune 30,Six Months EndedJune 30,
(in thousands, except share and per share amounts)2026202520262025
Net income$9,152$4,427$17,263$8,026
Basic - weighted-average shares outstanding:23,969,25423,900,39023,902,80224,018,119
Effect of dilutive securities:
Employee stock options and other446,534201,202455,766273,127
Diluted - weighted-average shares outstanding:24,415,78824,101,59224,358,56824,291,246
Net income per share:
Basic$0.38$0.19$0.72$0.33
Diluted$0.37$0.18$0.71$0.33

Note 4 –Goodwill and Other Intangible Assets

There wereno changes in the carrying amount of goodwill during the three and six months ended June 30, 2026.

Intangible assets other than goodwill at June 30, 2026 and December 31, 2025 were as follows:

June 30, 2026 · December 31, 2025 · UsefulLife (in years) · Weighted AverageUseful Life Remaining(in years)
(in thousands) · Gross · AccumulatedAmortization · Net · Gross · AccumulatedAmortization · Net
Intangible assets with finite lives:
Non-compete agreement$—$—$—$850$(843)$72.0 - 5.00
Software technology13,229(11,177)2,05213,229(10,493)2,73610.01.5
Software platform26,769(12,215)14,55427,110(11,241)15,86912.06.6
Total intangible assets$39,998$(23,392)$16,606$41,189$(22,577)$18,612

Intangible assets allocated to the Protolabs Network entities consisted of intangible assets of €11.6 million in Europe and $16.6 million in the United States as of the date of the acquisition. The Euro-denominated intangible assets are translated at the end of each period using the current exchange rates resulting in a foreign currency translation adjustment that is recorded as a component of Other Comprehensive Income. Foreign currency unrealized losses related to intangible assets were $0.9 million and $0.5 million as of June 30, 2026 and December 31, 2025, respectively. Amortization expense for intangible assets was $0.9 million for each of the three months ended June 30, 2026 and 2025, and $1.8 million for the six months ended June 30, 2026 and 2025, respectively.

Estimated aggregated amortization expense based on the current carrying value of the amortizable intangible assets and current exchange rates is as follows:

(in thousands)Estimated Amortization Expense
Remaining 2026$1,790
20273,578
20282,211
20292,211
20302,211
Thereafter4,605
Total estimated amortization expense$16,606

Note 5 –Fair Value Measurements

Accounting Standards Codification, Fair Value Measurement (ASC 820), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that arenot active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company's assets and liabilities that are required to be measured or disclosed at fair value on a recurring basis include cash and cash equivalents and marketable securities. The Company’s cash consists of bank deposits and cash equivalents consist primarily of money market mutual funds. The Company determines the fair value of these investments using Level 1 inputs. The Company's marketable securities consist of short-term and long-term agency, municipal, corporate and other debt securities. Fair value for the corporate debt securities is primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).

The following table summarizes financial assets as of June 30, 2026 and December 31, 2025 measured at fair value on a recurring basis:

June 30, 2026December 31, 2025
(in thousands)Level 1Level 2Level 3Level 1Level 2Level 3
Financial Assets:
Cash$124,766$—$—$107,462$—$—
Money market mutual fund3,152——3,364——
Marketable securities19,85615,122—18,30113,304—
Total$147,774$15,122$—$129,127$13,304$—

Note 6 –Marketable Securities

The Company invests in short-term and long-term agency, municipal, corporate and other debt securities. The securities are categorized as available-for-sale and are recorded at fair value. The following table summarizes information regarding the Company’s short-term and long-term marketable securities as of June 30, 2026 and December 31, 2025:

June 30, 2026
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$14,500$—$(58)$14,442
Corporate debt securities11,968—(108)11,860
U.S. municipal securities7,6795(8)7,676
U.S. treasury bonds1,000——1,000
Total marketable securities$35,147$5$(174)$34,978
December 31, 2025
(in thousands)CostUnrealized GainsUnrealized LossesFair Value
U.S. government agency securities$7,500$9$(4)$7,505
Corporate debt securities14,4249(7)14,426
U.S. municipal securities8,63139—8,670
U.S. treasury bonds1,0004—1,004
Total marketable securities$31,555$61$(11)$31,605

Fair values for the corporate debt securities are primarily determined based on quoted market prices (Level 1). Fair values for the U.S. municipal securities, U.S. government agency securities, certificates of deposit and U.S. treasury securities are primarily determined using dealer quotes or quoted market prices for similar securities (Level 2).

Classification of marketable securities as current or non-current is based upon the security’s maturity date as of the date of these financial statements.

The June 30, 2026 balance of available-for-sale debt securities by contractual maturity is shown in the following table at fair value. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

(in thousands)June 30,2026
Due in one year or less$14,858
Due after one year through five years20,120
Total marketable securities$34,978

Note 7 –Inventory

Inventory consists primarily of raw materials, which are recorded at the lower of cost and net realizable value using the standard cost method, which approximates first-in, first-out (FIFO) cost. The Company periodically reviews its inventory for slow-moving, damaged and discontinued items and provides allowances to reduce such items identified to their recoverable amounts.

The Company’s inventory consisted of the following as of the dates indicated:

(in thousands)June 30,2026December 31,2025
Total inventory$16,506$15,441
Allowance for obsolescence(1,093)(1,040)
Inventory, net of allowance$15,413$14,401

Note 8 –Stock-Based Compensation

On July 8, 2022, the board of directors approved the Proto Labs, Inc. 2022 Long-Term Incentive Plan, which was approved by the Company's shareholders at a Special Meeting of Shareholders on August 29, 2022, and subsequently amended and restated by the Company's shareholders at the Annual Meeting of Shareholders on May 23, 2024 (as amended and restated, and subsequently further amended, the 2022 Plan) to increase the number of shares available for issuance pursuant to awards under the 2022 Plan by an additional 430,000 shares, add a minimum vesting requirement, and extend the expiration date so that the term of the 2022 Plan runs forten years from the date of the shareholder approval. On May 20, 2025 and May 19, 2026, the Company's shareholders approved amendments to the 2022 Plan to increase the number of shares available for issuance pursuant to awards under the 2022 Plan by an additional 296,000 shares and 395,000 shares, respectively. Under the 2022 Plan, the Company has the ability to grant stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2022 Plan have a maximum term often years from the date of grant. The compensation and talent committee may provide that the vesting or payment of any award will be subject to the attainment of specified performance measures in addition to the satisfaction of any continued service requirements and the compensation and talent committee will determine whether such measures have been achieved. The per-share exercise price of stock options and SARs granted under the 2022 Plan generally may not be less than the fair market value of a share of our common stock on the date of the grant.

The Company also has outstanding awards under the 2012 Long-Term Incentive Plan, as amended (the 2012 Plan), although the plan expired in February 2022 and no additional awards have since been or will be made under the 2012 Plan. The 2012 Plan provided the Company the ability to grant stock options, SARs, restricted stock, restricted stock units, other stock-based awards and cash incentive awards. Awards under the 2012 Plan that subsequently expired, were forfeited or cancelled, or settled in cash after August 29, 2022 became available for awards under the 2022 Plan.

In addition, the Company has outstanding awards that were not granted under the 2022 Plan or the 2012 Plan. These awards were granted as inducement awards to the Company’s Chief Executive Officer in May 2025.

Employee Stock Purchase Plan

The Company’s 2012 Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase a variable number of shares of the Company’s common stock each offering period at a discount through payroll deductions of up to 15 percent of their eligible compensation, subject to plan limitations. The ESPP provides forsix-month offering periods with a single purchase period ending May 15 and November 15, respectively. At the end of each offering period, employees are able to purchase shares at 85 percent of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.

Stock-Based Compensation Expense

Stock-based compensation expense was $4.1 million and $4.3 million for the three months ended June 30, 2026 and 2025, respectively, and $7.3 million and $8.3 million for the six months ended June 30, 2026 and 2025, respectively.

Stock Options

The following table summarizes stock option activity during the six months ended June 30, 2026:

Stock OptionsWeighted-AverageExercise Price
Options outstanding at December 31, 2025360,214$52.94
Granted73,56065.22
Exercised(100,267)43.16
Forfeited(15,877)56.39
Expired(21,718)131.69
Options outstanding at June 30, 2026295,912$53.54
Exercisable at June 30, 2026114,024$61.44

The outstanding options generally have a term often years. For employees, options granted become exercisable ratably over the vesting period, which is generally a period offour years, beginning on the first anniversary of the grant date, subject to the employee’s continuing service to the Company.

The weighted-average grant date fair value of options that were granted during the six months ended June 30, 2026 was $35.95.

The following table provides the assumptions used in the Black-Scholes pricing model valuation of options during the six months ended June 30, 2026 and 2025:

Six Months EndedJune 30,
20262025
Risk-free interest rate3.71% - 4.28%4.13% - 4.17%
Expected life (years)6.256.25
Expected volatility52.59% - 52.69%52.12% - 52.99%
Expected dividend yield0%0%

As of June 30, 2026, there was $4.4 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 3.2 years.

Restricted Stock Units

Restricted stock unit (RSU) awards are share-settled awards and restrictions lapse ratably over the vesting period, which is generally a period offour years, beginning on the first anniversary of the grant date, subject to the employee's continuing service to the Company. For the board of directors, restrictions generally lapse in full on the first anniversary of the grant date.

The following table summarizes restricted stock units activity during the six months ended June 30, 2026:

RestrictedStock UnitsWeighted-AverageGrant DateFair ValuePer Share
Restricted stock units at December 31, 2025696,076$39.07
Granted140,39969.19
Restrictions lapsed(183,382)36.20
Forfeited(57,677)37.14
Restricted stock units at June 30, 2026595,416$47.31

As of June 30, 2026, there was $20.5 million of unrecognized compensation expense related to non-vested restricted stock units, which is expected to be recognized over a weighted-average period of 2.9 years.

Performance Stock Units

Performance stock units (PSUs) are expressed in terms of a target number of PSUs, with anywhere between 0 percent and 200 percent of that target number capable of being earned and vesting at the end of athree-year performance period depending on the Company’s three-year cumulative total shareholder return performance relative to an index and the award recipient’s continued employment. The Company’s PSUs are based on market conditions and the related compensation cost is based on the fair value at grant date calculated using a Monte Carlo pricing model.

The following table summarizes performance stock units activity during the six months ended June 30, 2026:

PerformanceStock UnitsWeighted-AverageGrant DateFair ValuePer Share
Performance stock units at December 31, 2025231,959$56.21
Granted64,217105.67
Restrictions lapsed(121,334)57.79
Performance change60,66757.79
Performance stock units at June 30, 2026235,509$69.29

The following table provides the assumptions used in the Monte Carlo pricing model valuation of PSUs during the six months ended June 30, 2026 and 2025:

Six Months EndedJune 30,
20262025
Risk-free interest rate3.48%3.98% - 4.08%
Expected life (years)2.852.61 - 2.85
Expected volatility47.40%52.40% - 53.20%
Expected dividend yield0%0%

As of June 30, 2026, there was $10.8 million of unrecognized compensation expense related to non-vested performance stock units, which is expected to be recognized over a weighted-average period of 2.2 years.

Employee Stock Purchase Plan

The following table presents the assumptions used to estimate the fair value of the ESPP during the six months ended June 30, 2026 and 2025:

Six Months EndedJune 30,
20262025
Risk-free interest rate3.67% - 3.78%4.29%
Expected life (months)6.006.00
Expected volatility39.13% - 46.79%65.60%
Expected dividend yield0%0%

Note 9 –Accumulated Other Comprehensive (Loss) Income

Other comprehensive (loss) income is comprised of foreign currency translation adjustments and net unrealized gains (losses) on investments in securities.

The following table presents the changes in accumulated other comprehensive (loss) income balances during the three and six months ended June 30, 2026 and 2025:

Three Months EndedJune 30,Six Months EndedJune 30,
(in thousands)2026202520262025
Balance at beginning of period$(23,487)$(26,891)$(20,976)$(27,984)
Foreign currency translation adjustments
Other comprehensive (loss) income before reclassifications2892,300(2,093)3,303
Amounts reclassified from accumulated other comprehensive loss————
Net current-period other comprehensive (loss) income2892,300(2,093)3,303
Net unrealized (losses) gains on investments in securities
Other comprehensive (loss) income before reclassifications(90)28(219)118
Amounts reclassified from accumulated other comprehensive loss————
Net current-period other comprehensive (loss) income(90)28(219)118
Balance at end of period$(23,288)$(24,563)$(23,288)$(24,563)

Note 10 –Income Taxes

The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the three months ended June 30, 2026 and 2025, the Company recorded an income tax provision of $3.5 million and $2.2 million, respectively. For the six months ended June 30, 2026 and 2025, the Company recorded an income tax provision of $6.7 million and $4.6 million, respectively. The income tax provision is based on the estimated annual effective tax rate for the year applied to pre-tax income. The effective income tax rate for the three months ended June 30, 2026 was 27.4 percent compared to 33.7 percent in the same period of the prior year. The effective tax rate decreased by 6.3 percent for the three months ended June 30, 2026 when compared to the same period in 2025, primarily due to an increase in tax benefits from the vesting of restricted stock and the exercise of stock options. The effective income tax rate for the six months ended June 30, 2026 was 27.8 percent compared to 36.6 percent in the same period of the prior year. The effective tax rate decreased by 8.8 percent for the six months ended June 30, 2026 when compared to the same period in 2025, primarily due to an increase in tax benefits from the vesting of restricted stock and the exercise of stock options, as well as tax benefits recognized on losses incurred by a newly established entity in India.

The effective income tax rate for the three and six months ended June 30, 2026 differs from the U.S. federal statutory rate of 21.0 percent due to various factors, including operating in multiple state and foreign jurisdictions partially offset by tax credits for which the Company qualifies.

The Company had unrecognized tax benefits totaling $3.2 million and $3.1 million as of June 30, 2026 and December 31, 2025, respectively, that if recognized would result in a reduction of the Company’s effective tax rate. The liabilities are classified as other long-term liabilities in the accompanying consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable as appropriate.

Note 11 –Segment Reporting

The Company’s reportable segments are based on the internal reporting used by the Company’s CEO, who is the chief operating decision maker (CODM), to assess operating performance and make decisions about the allocation of resources. The CODM's primary profit measure for purposes of resource allocation and performance assessment is income (loss) from operations at the segment level. This measure is used to evaluate current-period performance, develop forecasts and budgets, and make decisions about capital and other resource allocations between segments. The Company’s reportable segments are based upon geographic region, consisting of the United States and Europe. The Corporate Unallocated category includes non-reportable segments, as well as research and development and general and administrative costs that the Company does not allocate directly to its operating segments.

Revenue in the United States and Europe is derived primarily from Injection Molding, CNC Machining, 3D Printing and Sheet Metal product lines. Injection Molding revenue consists of sales of custom injection molds and injection-molded parts. CNC Machining revenue consists of sales of CNC-machined and lathe-turned customer parts. 3D Printing revenue consists of sales of 3D-printed parts. Sheet Metal revenue consists of sales of fabricated sheet metal parts.

Intercompany transactions primarily relate to intercontinental activity and have been eliminated and are excluded from the reported amounts. The difference between income (loss) from operations and pre-tax income relates to foreign currency-related gains and losses and interest income on cash balances and investments, which are not allocated to business segments.

The following table summarizes selected financial information by reportable segments:

Three Months Ended June 30, 2026
(in thousands)
United StatesEuropeCorporate UnallocatedTotal
Revenue$122,759$26,582$—$149,341
Segment expenses185,09531,29119,736136,122
Restructuring and transformation costs—924—924
Costs related to exit and disposal activities—937—937
Income (Loss) from Operations$37,664$(6,570)$(19,736)$11,358
Three Months Ended June 30, 2025
(in thousands)
United StatesEuropeCorporate UnallocatedTotal
Revenue$110,712$24,351$—$135,063
Segment expenses183,02529,17017,750129,945
Costs related to exit and disposal activities—149—149
Income (Loss) from Operations$27,687$(4,968)$(17,750)$4,969
Six Months Ended June 30, 2026
(in thousands)
United StatesEuropeCorporate UnallocatedTotal
Revenue$234,886$53,791$—$288,677
Segment expenses1164,25362,33937,606264,198
Restructuring and transformation costs—2,0143312,345
Costs related to exit and disposal activities—937—937
Income (Loss) from Operations$70,633$(11,499)$(37,937)$21,197
Six Months Ended June 30, 2025
(in thousands)
United StatesEuropeCorporate UnallocatedTotal
Revenue$210,979$50,289$—$261,268
Segment expenses1157,79558,97034,893251,658
Costs related to exit and disposal activities—110—110
Income (Loss) from Operations$53,184$(8,791)$(34,893)$9,500

1 Segment expenses consist primarily of raw materials, equipment depreciation, employee compensation including benefits, commissions and stock-based compensation, facilities costs and overhead allocations associated with the manufacturing process for molds and custom parts, marketing programs such as electronic, print and pay-per-click advertising and trade shows and other related costs for our United States and Europe reportable segments. Segment expenses for our Corporate Unallocated reportable segment consist primarily of personnel and outside service costs related to the development of new processes and product lines, enhancements of existing product lines, software developed for internal use, maintenance of internally developed software, quality assurance and testing, employee compensation including benefits and stock-based compensation, severance, professional service fees related to accounting, tax and legal, and other related overhead costs.

Total long-lived assets, expenditures for additions to long-lived assets, and depreciation and amortization expense were as follows:

(in thousands)June 30,2026December 31,2025
Total long-lived assets:
United States$165,786$170,228
Europe42,54345,033
Total Long-lived Assets$208,329$215,261
Three Months EndedJune 30,Six Months EndedJune 30,
(in thousands)2026202520262025
Expenditures for additions to long-lived assets:
United States$5,658$1,125$8,859$2,293
Europe545343884437
Total expenditures for additions to long-lived assets$6,203$1,468$9,743$2,730
Three Months EndedJune 30,Six Months EndedJune 30,
(in thousands)2026202520262025
Depreciation and Amortization:
United States$6,698$7,003$13,309$14,012
Europe1,3841,4842,8193,090
Corporate Unallocated683$33$162
Total depreciation and amortization$8,088$8,570$16,161$17,264

Revenue by product line for the three and six months ended June 30, 2026 and 2025 were as follows:

Three Months EndedJune 30,Six Months EndedJune 30,
(dollars in thousands)2026202520262025
Revenue:
Injection Molding$53,625$47,415$104,693$96,138
CNC Machining70,36061,945133,605114,788
3D Printing20,66721,21541,13241,409
Sheet Metal4,4624,3038,8138,514
Other Revenue227185434419
Total revenue$149,341$135,063$288,677$261,268
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.